KR950704484A - 전사인자 DP-1(Transcription factor DP-1) - Google Patents

전사인자 DP-1(Transcription factor DP-1)

Info

Publication number
KR950704484A
KR950704484A KR1019950701639A KR19950701639A KR950704484A KR 950704484 A KR950704484 A KR 950704484A KR 1019950701639 A KR1019950701639 A KR 1019950701639A KR 19950701639 A KR19950701639 A KR 19950701639A KR 950704484 A KR950704484 A KR 950704484A
Authority
KR
South Korea
Prior art keywords
polynucleotide
polypeptide
antibody
protein
seq
Prior art date
Application number
KR1019950701639A
Other languages
English (en)
Inventor
배리 라 탕그 니콜라스
Original Assignee
마틴 알. 우드.
메디칼 리써치 카운실
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929222715A external-priority patent/GB9222715D0/en
Priority claimed from GB939316206A external-priority patent/GB9316206D0/en
Application filed by 마틴 알. 우드., 메디칼 리써치 카운실 filed Critical 마틴 알. 우드.
Publication of KR950704484A publication Critical patent/KR950704484A/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

본 발명은 서열확인번호 1또는 서열확인번호 1의 상보체에 선택적으로 하이브리드화될 수 있는 인접한 뉴클레오타이드 서열을 포함하는 실질적으로 분리된 형태의 폴리뉴클레오타이드, 및 (a)서열확인번호 2의 단백질, (b)대립 유전자 변이체 또는 이의 종 동족체, (c) (a)와 70% 이상 동질성인 단백질, (d) E2F-1단백질 또는 관련 부류 구성원과 복합체를 형성할 수 있는 (a)내지 (c)중 어느 하나의 단편 또는 (e)15개 이상의 아미노산의 (a)내지 (C)중 어느하나의 단편을 포함하는, 실질적으로 분리된 형태의 폴리펩타이드를 제공한다.

Description

전사인자 DP-1(Transcription factor DP-1)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 F9 EC 세포로부터의 DP-1의 친화 정제의 결과를 나타낸다,
제2도는 DP-1이 E2F 복합체에서 DNA 결합 폴리펩타이드임을 나타내고 있다.
제3도는 DP-1이 서열 특이적 DNA 결합을 나타낸다.

Claims (32)

  1. 서열확인번호 1 또는 서열확인번호 1의 상보체에 선택적으로 하이브리드화될 수 있는 이웃한 뉴클레오타이드 서열을 포함하는, 실질적으로 분리된 형태의 폴리뉴클레오타이드.
  2. 제1항에 있어서, DNA 폴리뉴클레오타이드인 폴리뉴클레오타이드.
  3. 제1항 또는 제2항에 있어서, 이웃한 서열이 20개 이상의 뉴클레오타이드를 포함하는 폴리뉴클레오타이드.
  4. 제3항에 있어서 서열확인번호 1을 포함하는 폴리뉴클레오타이드.
  5. 제1항 내지 제4항중 어느 한 항에 따른 폴리뉴클레오타이드 및 이의 상보체를 포함하는 이본쇄 폴리뉴클레오타이드.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, 현시용 표지를 지니는 폴리뉴클레오타이드.
  7. 제1항 내지 제6항중 어느 한 항에 따른 폴리뉴클레오타이드를 포함하는 재조합 복제성 벡터.
  8. 제7항에 따른 벡터를 포함하는 숙주세포.
  9. (a)서열확인번호 2의 단백질, (b)대립 유전자 변이체 또는 이의 종 동족체, (c) (a)와 70% 이상 동질성인 단백질, (d)E2F-1 단백질 또는 관련 부류 구성원과 복합체를 형성할 수 있는 (a)내지 (c)중 어느 하나의 단편, 또는 (e)15개 이상의 아미노산의 (a)내지 (c)중 어느 하나의 단편을 포함하는, 실질적으로 분리된 형태의 폴리펩타이드.
  10. 제9항에 있어서, 현시용 표지를 지니는 폴리펩타이드.
  11. 담체 또는 희석제와 함께 제9항 또는 제10항에 따른 폴리펩타이드를 포함하는 조성물.
  12. 제9항 또는 제10항에 있어서, 고체상에 고정시킨 폴리펩타이드.
  13. 제9항에서 정의된 폴리펩타이드를 암호화하는 이본쇄 DNA.
  14. 제9항에서 정의된 바와 같은 폴리펩타이드를 암호화하는 암호화 서열을 포함하는 재조합 복제성 벡터.
  15. 제14항에 따른 재조합 벡터로 형질전환시킨 숙주 세포.
  16. 암호화 서열이, 숙주세포에 의한 암호화 서열이 발현을 제공할 수 있는 조절 서열에 작동적으로 연결된, 제14항에 따른 제조합 벡터로 형질전환시킨 숙주세포.
  17. 제16항에 따른 숙주세포를, 재조합 벡터에 의한 암호화 서열의 발현을 위해 제공된 조건하에서 배양하고, 이로써 발현된 폴리펩타이드를 회수함을 포함하여, 제9항에 따른 폴리펩타이드를 제조하는 방법.
  18. (a)서열확인번호 2의 단백질, (b) 대립 유전자 변이체 또는 이의 종 동족체, (c) (a)와 70% 이상 동질성인 단백질, (d)E2F-1 단백질 는 관련 부류 구성원과 복합체를 형성할 수 있는 (a)내지 (c)중 어느 하나의 단편, 또는 (e)15개 이상의 아미노산의 (a)내지 (c)중 어느 하나의 단편에 결합할 수 있는 항체.
  19. 제18항에 있어서, 모노클로날 항체인 항체.
  20. 제18항 또는 제19항에 있어서, 현시용 표지를 지니는 항체.
  21. 제18항 내지 제20중에 어느 한 항에 있어서, 고체상에 고정시킨 항체.
  22. 제19항에 따른 모노클로날 항체를 생성하는 하이브리드마세포주.
  23. (a)제18항 내지 제21항중 어느 한 항에 따른 항체를 제공하고, (b)샘플과 항체를 항체-항원 복합체를 형성하도록 하는 조건하에서 배양하며, (c)상기 항체-항원 복합체를 검출함을 포함하며, 샘플중에서 제9항에 따른 폴리펩타이드의 존재 또는 부재를 검출하기 위한 면역 분석.
  24. (A) (i)제9항 또는 제10항에 따른 폴리펩타이드, (ii) (a)E2F-1 단백질, (b)대립 유전자 변이체 또는 이의 종 동족체, (c)DNA 결합 영역에 대해 70% 이상의 상동성을 갖는 E2F-1부류 구성원, (b)서열확인번호 2의 단백질과 작용성 트랜스-활성화 복합체를 형성할 수 있는 (a), (b) 또는 (c)의 단편 또는 (e) (a), (b), (c) 또는 (d)를 포함하는 융합 단백질 및 (iii)가상의 화학요법제를 (iii)의 부재하에서는 성분(i)과 (ii)가 복합체를 형성하는 조건하에서 서로 접촉시키고 (B) 성분(iii)이 상기 복합체의 활성을 파괴시키거나 억제시킬 수 있는 정도를 측정함을 포함하여, 증식성 또는 바이러스성 질환의 치료률 위한 가상의 화학 요법제를 동정해 내기 위한 스크리닝 방법.
  25. 제23항에 있어서, (i)과 (ii)의 복합체를, 시험관내에서 E2F DNA 결합 부위에 결합하는 이의 능력으로 측정하는 분석.
  26. 제23항에 있어서, (i)과 (ii)의 복합체를, 생체내에서 리포터 유전자에 결합된 E2F 결합 부위를 포함하는 프로모터를 활성화시키는 이의 능력으로 측정하는 분석.
  27. 제26항에 있어서, 효모세포, 곤충세포 또는 포유류 세포내에서 수행되는 분석.
  28. 제23항 내지 제26항중 어느 한 항에 있어서, 가상의 화학요법제가 (a)서열확인번호 2의 단백질, (b)대립 유전자 변이체 또는 이의 포유류 동족체, 또는 (c) (a)와 70%이상 동질성인 단백질의 10개 이상 아미노산의 단편인 분석.
  29. 제28항에 있어서, 단편이 서열확인번호 2의 160 내지 220의 영역내에 포함되는 폴리펩타이드 단편인 분석.
  30. 사람 또는 동물의 치료법에 사용하기 위한, 제9항 또는 제10항의 따른 폴리펩타이드 또는 제8항 내지 제27항중 어느 한항에 따른 항체.
  31. 사람 또는 동물의 치료법에 사용하기 위한, 제7항 또는 제14항에 따른 벡터.
  32. 치료를 필요로 하는 환자에게 유효량의 제7항 또는 제14항에 따른 벡터 또는 제1항에 따른 폴리뉴클레오타이드를 투여함을 포함하여, 상기 환자에게 조절되지 않는 세포증식을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701639A 1992-10-29 1993-10-29 전사인자 DP-1(Transcription factor DP-1) KR950704484A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929222715A GB9222715D0 (en) 1992-10-29 1992-10-29 Transcription factor
GB9316206.3 1993-08-05
GB939316206A GB9316206D0 (en) 1993-08-05 1993-08-05 Transcription factor
GB9222715.6 1993-08-05
PCT/GB1993/002227 WO1994010307A1 (en) 1992-10-29 1993-10-29 Transcription factor dp-1

Publications (1)

Publication Number Publication Date
KR950704484A true KR950704484A (ko) 1995-11-20

Family

ID=26301878

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701639A KR950704484A (ko) 1992-10-29 1993-10-29 전사인자 DP-1(Transcription factor DP-1)

Country Status (12)

Country Link
US (2) US5863757A (ko)
EP (2) EP0905236A1 (ko)
JP (1) JP3633616B2 (ko)
KR (1) KR950704484A (ko)
AT (1) ATE181360T1 (ko)
AU (1) AU675678B2 (ko)
CA (1) CA2148258A1 (ko)
DE (1) DE69325383T2 (ko)
DK (1) DK0669976T3 (ko)
NO (1) NO323532B1 (ko)
NZ (1) NZ257181A (ko)
WO (1) WO1994010307A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
GB9413327D0 (en) * 1994-07-01 1994-08-24 Medical Res Council Assay for inhibitors of dp-1
US6303335B1 (en) 1994-11-15 2001-10-16 Prolifix Limited Transcription factor E2F-4
EP0792359B1 (en) * 1994-11-15 2008-11-12 TopoTarget UK Limited Transcription factor e2f-4
GB9502873D0 (en) * 1995-02-14 1995-04-05 Medical Res Council Transcription factor
US5705350A (en) * 1995-08-29 1998-01-06 Duke University Transcription factor complexes in senescent cells
GB9608143D0 (en) * 1996-04-19 1996-06-26 Ver Nl Kanker Inst Assay
US6159691A (en) * 1996-05-15 2000-12-12 Prolifix Limited Assay for a putative regulator of cell cycle progression
GB9610195D0 (en) * 1996-05-15 1996-07-24 Medical Res Council Assay
FR2750705B1 (fr) * 1996-07-04 1998-10-30 Centre Nat Rech Scient Systeme de detection des interactions proteine-proteine
US6713449B1 (en) * 1996-09-30 2004-03-30 Kyowa Hakko Kogyo Co., Ltd. E2F activity inhibitory compounds
US6387649B1 (en) 1996-09-30 2002-05-14 Prolifix Limited Assay for a regulator of cell cycle progression
GB9626589D0 (en) * 1996-12-20 1997-02-05 Prolifix Ltd Peptides
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
WO1999020752A1 (en) 1997-10-21 1999-04-29 The University Court Of The University Of Glasgow JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF
EP1068334A2 (en) * 1998-04-09 2001-01-17 E.I. Du Pont De Nemours And Company Cell cycle regulatory proteins cdc-16, dp-1, dp-2 and e2f from plants
WO2001020335A2 (en) * 1999-09-16 2001-03-22 Mcgill University Methods for modulating cell proliferation
EP1214436A2 (en) * 1999-09-24 2002-06-19 Consejo Superior De Investigaciones Cientificas Wheat dp proteins and uses thereof
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US20030225012A1 (en) * 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of transcription factor DP-1 expression
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
NZ550600A (en) 2004-04-28 2010-03-26 Btg Int Ltd Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015227A1 (en) * 1992-01-29 1993-08-05 Duke University Method of assaying for the oncogenic state of cells

Also Published As

Publication number Publication date
AU5343994A (en) 1994-05-24
NO951641D0 (no) 1995-04-28
AU675678B2 (en) 1997-02-13
NO323532B1 (no) 2007-06-04
JP3633616B2 (ja) 2005-03-30
DK0669976T3 (da) 2000-01-10
DE69325383T2 (de) 1999-11-25
US6150116A (en) 2000-11-21
CA2148258A1 (en) 1994-05-11
WO1994010307A1 (en) 1994-05-11
EP0669976A1 (en) 1995-09-06
DE69325383D1 (de) 1999-07-22
NO951641L (no) 1995-06-29
EP0905236A1 (en) 1999-03-31
JPH08503128A (ja) 1996-04-09
NZ257181A (en) 1997-07-27
ATE181360T1 (de) 1999-07-15
EP0669976B1 (en) 1999-06-16
US5863757A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
KR950704484A (ko) 전사인자 DP-1(Transcription factor DP-1)
Worwood Ferritin
Pober et al. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.
Sun et al. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection
Sylvester et al. Induction of GADD153, a CCAAT/enhancer-binding protein (C/EBP)-related gene, during the acute phase response in rats. Evidence for the involvement of C/EBPs in regulating its expression.
Comeau et al. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR
Traut et al. Ribosomal proteins of Escherichia coli. I. Demonstration of different primary structures.
Tanabe et al. An embryonic/fetal β‐type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer
CA2413857A1 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
TAKIYA et al. Transcriptional regulatory elements in the upstream and intron of the fibroin gene bind three specific factors POU-M1, Bm Fkh and FMBP-1
Roux et al. The cell-specific transcription factor PTF1 contains two different subunits that interact with the DNA.
JP2002518010A5 (ko)
CA2353086A1 (en) Pgc-1, a novel brown fat ppar.gamma. coactivator
CA2290944A1 (en) Pgc-1, a novel brown fat ppar.gamma. coactivator
Conti-Tronconi et al. Molecular weight and structural nonequivalence of the mature alpha subunits of Torpedo californica acetylcholine receptor.
CA2165297A1 (en) Myeloid cell leukemia associated gene mcl-1
FI101476B1 (fi) Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi
CA2302808A1 (en) 50 human secreted proteins
RU2002103870A (ru) Человеческое моноклональное антитело против AILIM, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
Rasmussen et al. Structure of the human oxytocinase/insulin‐regulated aminopeptidase gene and localization to chromosome 5q21
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
Saisanit et al. Regulation of the pro-B-cell-specific enhancer of the Id1 gene involves the C/EBP family of proteins
KR970704887A (ko) 혈청 파라옥소나제
Hein et al. Ubiquitination and dimerization of complement receptor type 2 on sheep B cells
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid